Search results: (10000)
News San Antonio: Results of Breast Cancer Treatment with Combination of Pertuzumab, Trastuzumab, and AI After 6 Years
The virtual conference dedicated to breast cancer, which took place December 8–11 in San Antonio, USA (San Antonio Breast Cancer Symposium; SABCS 2020), presented, among other things, the results of the final analysis of the multicenter randomized open-label PERTAIN study.
News Turoctocog Alfa Pegol and Its Impact on Health-Related Quality of Life
The presented work is based on the results of studies that evaluated how the administration of turoctocog alfa pegol affects the quality of life in individuals with severe hemophilia A. The obtained data also reflect the level of patient satisfaction with this treatment.
News Do antiglaucoma drugs induce inflammation and irritation on the eye surface? Results of a 2-year randomized study
Eye drops for glaucoma treatment may contain preservatives responsible for eye irritation and possibly chronic inflammation. The study presented below is the first to compare the profile of inflammatory cytokines and eye irritation in patients using topical antiglaucoma drugs with and without preservatives.
News How Will the New Player in Dyslipidemia Therapy Change the "Rules of the Game"?
Inclisiran, as an innovative drug indicated for adult patients with primary hypercholesterolemia or mixed dyslipidemia, was registered in the European Union at the end of 2020. Internists and cardiologists can now share their first experiences with this therapy in real practice. Case reports from the Czech Republic have also been published in specialized literature.
News Pharmacokinetic Comparison of Two EHL Products in Hemophilia A
According to a Canadian study published last year, certain pharmacokinetic differences were observed between two extended half-life factors.
News Monitoring of Joint Health is an Important Part of Hemophilia Care
Joint health has become a key aspect of the quality of life for people with hemophilia. The possibilities of monitoring early joint damage in hemophiliacs were evaluated in a recently published British study.
News Rurioctocog alfa pegol in previously treated patients with severe hemophilia A: What findings did the long-term continuation study bring?
Rurioctocog alfa pegol (Adynovi) is a recombinant coagulation factor VIII modified by pegylation, which results in an approximately 1.5× prolonged biological half-life compared to standard half-life FVIII. Previous studies have already confirmed the favorable profile of this drug in prophylaxis for patients with hemophilia A. Recently published results of a prospective multicenter continuation study in children and adult patients under 75 years old with severe hemophilia A (baseline FVIII level < 1%) were based on an observation period averaging 2.2 years.
News Issues of Adherence to Thromboprophylaxis with Enoxaparin in Patients with Sickle Cell Disease
Thromboembolic disease is one of the common complications in patients with sickle cell disease (SCD). However, a recently published study shows that patient adherence to prescribed thromboprophylaxis is not very high.
News ASH 2020: Efficacy and Safety of Emicizumab in Long-term Follow-up
At the virtual meeting of the American Society of Hematology (ASH) in December 2020, the latest data concerning the long-term follow-up of participants in the HAVEN 1−4 clinical trials with emicizumab were published.
News What does the analysis of the CHESS PAEDs study say about the relationship between physical activity and the frequency of bleeding events in children with hemophilia A?
Currently, there is limited published data addressing the relationship between physical activity and the occurrence of bleeding events in children with hemophilia A. To gain insights into this topic in real-world practice, data from the CHESS PAEDs study were analyzed. The results were presented in the poster section of the virtual congress of the International Society on Thrombosis and Haemostasis (ISTH).
News ASH 2020: Two Real-World Perspectives on Experiences with Emicizumab Prophylaxis
Data presented at the ASH 2020 congress bring interesting insights regarding the administration of emicizumab in real clinical practice. It provides comprehensive information on the relatively high number of individuals treated with emicizumab in relation to persistence on treatment and adherence to it. Data from the EUHASS registry confirms the good safety profile of this treatment even in regular clinical practice across Europe.
News ESC 2022: What Do the Latest Real-World Data Say About the Use of DOACs in Atrial Fibrillation?
Why are real-world data so important? What new insights can they provide about established medications, such as direct oral anticoagulants (DOACs), in the treatment of patients with atrial fibrillation (AF)? What makes the GLORIA-AF registry unique, and what insights have been published from it this year? These topics were also discussed at the ESC 2022 Congress.
News European Registry of Patients with Alpha-1 Antitrypsin Deficiency EARCO Enrolls Patients
Insufficient identification of patients with alpha-1 antitrypsin deficiency (AATD) and a lack of knowledge about this disease have led to the launch of the European Registry EARCO, which is currently enrolling patients. The aim is to better describe the pathophysiology of the disease and the prognosis of these patients, and to create a validated prognostic tool to aid clinical decision-making.
News Safety and efficacy of dabigatran and other NOACs compared with warfarin in patients with atrial fibrillation – results of a large long-term prospective study
Anticoagulant therapy is key in the prevention of strokes in patients with atrial fibrillation. Until the introduction of new oral anticoagulants (NOACs), warfarin was the first-choice drug for these patients, but unlike NOACs, it requires careful dose titration and effect monitoring. The safety and benefits of using various anticoagulants were examined in the study below.
News Turoctocog Alfa Pegol with Extended Half-Life in the Treatment of Severe Hemophilia A
GlycoPEGylated recombinant factor VIII (rFVIII) with an extended half-life, turoctocog alfa pegol, has demonstrated prophylactic efficacy in patients with severe hemophilia A aged over 12. This product is administered only once every 4 days. In addition to a comparable reduction in the annual bleed rate to standard FVIII prophylaxis products, it has also shown sufficient efficacy in bleeding treatment and a minimal risk of inhibitory antibody formation.
News Intravenous Fixed Combination NEPA in the Prevention of Chemotherapy-Induced Vomiting
Summary data from several studies were used by the authors of the following analysis to evaluate the efficacy of the intravenous and oral forms of the fixed combination NEPA (netupitant/fosnetupitant + palonosetron) administered with dexamethasone in preventing chemotherapy-induced vomiting based on cisplatin or anthracycline and cyclophosphamide (AC).
News Heart Failure in the Light of New ESC Guidelines
Dear Doctor, The Czech Society of Internal Medicine of ČLS JEP invites you to watch the symposium, which will take place on Wednesday, November 3rd, at 5 PM.
You can find more information in the invitation attached below.
You can find more information in the invitation attached below.
News Improvement of Executive Functions in Therapy of Dravet Syndrome with Fenfluramine in Preschool Children
Dravet syndrome is a rare genetic progressive epileptic encephalopathy that is usually accompanied by intellectual and behavioral disorders. Many children with this syndrome also struggle with deficits in executive functions. An analysis recently published in the journal Epilepsy & Behavior assessed the impact of fenfluramine therapy on executive functions in preschool children with this condition.
News Immunotolerance is still the goal of management of hemophilia A with inhibitor in the era of non-factor therapy
New molecules in hemophilia therapy have raised many questions, including regarding the significance and need for immune tolerance induction (ITI). Interesting conclusions from the FIT (Future of Immunotolerance Treatment) expert panel discussion on the future of ITI, its form, and indication were published in July 2019.
News Population Pharmacokinetics of Perioperative Administration of Coagulation Factors in Patients with von Willebrand Disease
For many patients with von Willebrand disease, the administration of coagulation factors is an important part of perioperative care. Due to the absence of pharmacokinetic models, predicting therapeutic levels is challenging, leading to a higher risk of bleeding or thrombotic events. To create the missing model, a long-term study was conducted by Dutch authors.
News How to Improve Diabetic Adherence?
The dream of every doctor is a conscientious patient who follows the prescribed treatment and reports any potential problems in a timely manner. But where can such a patient be found?
News In decisions about therapeutic strategy in multiple myeloma, patient preferences and concerns also play a crucial role
The perspective on the preferences of patients with multiple myeloma (MM) is very necessary at a time of rapid development of new treatment options. Patient priorities and their perception of treatment can, alongside the assessment of the efficacy or toxicity of a modality, also influence decisions about the therapeutic strategy.
News Efficacy and Safety of High Doses of Enoxaparin in Preventing Thromboembolic Disease in Morbidly Obese Patients
Thromboembolic disease is a significant cause of morbidity and mortality in hospitalized patients, with morbid obesity being a notable risk factor for thromboembolism. Various thromboprophylaxis strategies have been studied in morbidly obese patients; a recently published study compared the efficacy and safety of high doses of enoxaparin and unfractionated heparin.
News Are All Patients Really Suitable for Thromboprophylaxis Treated This Way?
A study published this year aimed to assess how often the risk of VTE is assessed in routine clinical practice in internally ill patients, what proportion of patients are suitable for thromboprophylaxis, and how many actually receive this treatment.
News Effect of Empagliflozin on Clinical Stability in Patients with Heart Failure and Reduced LV Ejection Fraction
Previous studies have shown that the oral antidiabetic drug empagliflozin reduces the risk of death from cardiovascular causes or hospitalization for heart failure in patients with heart failure with reduced left ventricular ejection fraction (HFrEF), both in diabetic and non-diabetic patients. The aim of the EMPEROR-Reduced clinical study was to supplement data on the effect of empagliflozin on the incidence of heart failure worsening events requiring hospitalization or outpatient treatment.